mAb and bsAb Platform:
Kelun-Biotech has established an advanced and efficient full-process R&D platform for biologics. The Company’s world-class professional and scientific teams provide high-quality mAb, bsAb and ADC drugs for the biologics innovative drug pipeline.
Antibody discovery platform: Includes highly efficient and optimized animal immunology (cell, protein, DNA) and hybridoma fusion technology, large pool of human phage library and diversified screening solutions, as well as single B cell antibody discovery, etc.
Antibody evaluation platform: Includes high-throughput natural conformation target screening technology, high-throughput endocytic screening evaluation (ADC) and strict and diversified in vivo and in vitro drug efficacy analysis based on physiological functions. The platform has established drug efficacy research methods, antibody drugability and immunogenicity analysis for diseases such as tumors, autoimmunity and metabolism.
Antibody engineering platform: Includes antibody humanization and physicochemical property modification, and affinity maturation based on structure and library screening.
Engineering cell line platform: Includes a high-yield and stable production cell line construction, a document system that meets global regulatory requirements. A number of projects have applied and have been approved in China and the United States. It is a mature and one-stop drug R&D system, which has completed the R&D and application of more than ten biologics projects, and achieved excellent efficacy in clinical trials.